Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

News · November 04, 2023

ESMO 2023: Amivantamab + Lazertinib OK for First-Line EGFR-Mutated Non-Small Cell Lung Cancer

Phase 3 trial shows significant reduction in disease progression, death versus osimertinib at 22.0 months for treatment-naïve advanced disease

PracticeUpdate Editorial Team


Further Reading